Cargando…
Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma(☆)
Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a gre...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771890/ https://www.ncbi.nlm.nih.gov/pubmed/33384879 http://dx.doi.org/10.1016/j.livres.2020.11.003 |